scholarly journals High Prevalence of Simian T-Lymphotropic Virus Type L in Wild Ethiopian Baboons

2002 ◽  
Vol 76 (4) ◽  
pp. 1642-1648 ◽  
Author(s):  
Taichiro Takemura ◽  
Masahiro Yamashita ◽  
Makoto K. Shimada ◽  
Sadayuki Ohkura ◽  
Takayoshi Shotake ◽  
...  

ABSTRACT Simian T-cell leukemia viruses (STLVs) are the simian counterparts of human T-cell leukemia viruses (HTLVs). A novel, divergent type of STLV (STLV-L) from captive baboons was reported in 1994, but its natural prevalence remained unclear. We investigated the prevalence of STLV-L in 519 blood samples from wild-living nonhuman primates in Ethiopia. Seropositive monkeys having cross-reactive antibodies against HTLV were found among 22 out of 40 hamadryas baboons, 8 of 96 anubis baboons, 24 of 50 baboons that are hybrids between hamadryas and anubis baboons, and 41 of 177 grivet monkeys, but not in 156 gelada baboons. A Western blotting assay showed that sera obtained from seropositive hamadryas and hybrid baboons exhibited STLV-L-like reactivity. A PCR assay successfully amplified STLV sequences, which were subsequently sequenced and confirmed as being closely related to STLV-L. Surprisingly, further PCR showed that nearly half of the hamadryas (20 out of 40) and hybrid (19 out of 50) baboons had STLV-L DNA sequences. In contrast, most of the seropositive anubis baboons and grivet monkeys carried typical STLV-1 but not STLV-L. These observations demonstrate that STLV-L naturally prevails among hamadryas and hybrid baboons at significantly high rates. STLV-1 and -2, the close relative of STLV-L, are believed to have jumped across simian-human barriers, which resulted in widespread infection of HTLV-1 and -2. Further studies are required to know if STLV-L is spreading into human populations.

Science ◽  
1984 ◽  
Vol 226 (4670) ◽  
pp. 61-65 ◽  
Author(s):  
D. Slamon ◽  
K Shimotohno ◽  
M. Cline ◽  
D. Golde ◽  
I. Chen

Blood ◽  
1985 ◽  
Vol 65 (2) ◽  
pp. 492-495 ◽  
Author(s):  
JJ Goedert ◽  
MG Sarngadharan ◽  
ME Eyster ◽  
SH Weiss ◽  
AJ Bodner ◽  
...  

Abstract The third member of the family of T cell leukemia viruses (HTLV III) has been proposed as the primary etiologic agent of the acquired immunodeficiency syndrome (AIDS). A high risk of AIDS has been reported among patients with hemophilia, particularly those with factor VIII deficiency who receive commercial clotting factor concentrates. In a prevalence survey conducted between September 1982 and April 1984, initial serum samples from 74% of hemophiliacs who had ever been treated with commercial factor VIII concentrate, 90% of those frequently treated with factor VIII concentrate, and 50% of those treated with both factor VIII and factor IX concentrates had antibodies reactive against antigens of HTLV III, compared with none of the hemophiliacs treated only with factor IX concentrate or volunteer donor plasma or cryoprecipitate. Two of the seropositive patients have developed AIDS-related illnesses, and a third patient died of bacterial pneumonia. One initially seronegative patient developed antibodies against HTLV III during the study and is currently well. The predominant antibody specificities appear directed against p24 and p41, the presumed core and envelope antigens of HTLV III, suggesting that factor VIII concentrate may transmit the p24 and p41 antigens of HTLV III. However, the presence of infectious retroviruses in clotting factor concentrates and the effectiveness of screening and viral neutralization procedures remain to be determined.


Science ◽  
1984 ◽  
Vol 225 (4665) ◽  
pp. 927-930 ◽  
Author(s):  
S. Arya ◽  
R. Gallo ◽  
B. Hahn ◽  
G. Shaw ◽  
M Popovic ◽  
...  

Blood ◽  
1985 ◽  
Vol 65 (2) ◽  
pp. 492-495
Author(s):  
JJ Goedert ◽  
MG Sarngadharan ◽  
ME Eyster ◽  
SH Weiss ◽  
AJ Bodner ◽  
...  

The third member of the family of T cell leukemia viruses (HTLV III) has been proposed as the primary etiologic agent of the acquired immunodeficiency syndrome (AIDS). A high risk of AIDS has been reported among patients with hemophilia, particularly those with factor VIII deficiency who receive commercial clotting factor concentrates. In a prevalence survey conducted between September 1982 and April 1984, initial serum samples from 74% of hemophiliacs who had ever been treated with commercial factor VIII concentrate, 90% of those frequently treated with factor VIII concentrate, and 50% of those treated with both factor VIII and factor IX concentrates had antibodies reactive against antigens of HTLV III, compared with none of the hemophiliacs treated only with factor IX concentrate or volunteer donor plasma or cryoprecipitate. Two of the seropositive patients have developed AIDS-related illnesses, and a third patient died of bacterial pneumonia. One initially seronegative patient developed antibodies against HTLV III during the study and is currently well. The predominant antibody specificities appear directed against p24 and p41, the presumed core and envelope antigens of HTLV III, suggesting that factor VIII concentrate may transmit the p24 and p41 antigens of HTLV III. However, the presence of infectious retroviruses in clotting factor concentrates and the effectiveness of screening and viral neutralization procedures remain to be determined.


1995 ◽  
Vol 69 (2) ◽  
pp. 1328-1333 ◽  
Author(s):  
G Feuer ◽  
S A Stewart ◽  
S M Baird ◽  
F Lee ◽  
R Feuer ◽  
...  

1989 ◽  
pp. 113-125
Author(s):  
Irvin S.Y. Chen ◽  
Alan J. Cann ◽  
James P. Lugo ◽  
Joseph D. Rosenblatt

1990 ◽  
Vol 162 (6) ◽  
pp. 1370-1372 ◽  
Author(s):  
R. D. Meyer ◽  
T. Moudgil ◽  
R. Detels ◽  
J. P. Phair ◽  
M. S. Hirsch ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document